Sentences with phrase «generation technology based»

Not exact matches

Quebecor is also expected to invest in its Videotron networks and the introduction of a new generation of home cable technology based on Comcast's X1 platform, which is being rolled out by most of Canada's major cable services to compete with their telephone - based market rivals.

It's not just next - generation West Coast startups heeding the call, either: In 2013, more than 90 percent of Zenefits customers called California home and 80 percent identified as technology firms; today more than half of all businesses using Zenefits services are based outside the Golden State and operate in sectors other than tech.

Ping Li of Accel Partners discusses the company's investment in next - generation data - based technology, including Cloudera, Nimble Storage and Sumo Logic.

Pai said after a staff review he was urging approval for SpaceX, saying: «it would be the first approval given to an American - based company to provide broadband services using a new generation of low - Earth orbit satellite technologies.

As much as this is about Bluelime, it is more about our loyal and impressive client base in Utilities, Transmissions, Distribution, Power Generation and Information Technology.

LONDON and NEW YORK, May 3, 2018 / PRNewswire / — Motive Labs, the global innovation firm focused on building the next generation of financial technology, announced today that it has formed a strategic partnership based on value creation with Inforalgo, a leading provider of data connectivity and...

Using lifecycle analysis, a study conducted by Environment Canada and Natural Resources Canada found that while all forms of electricity generation have environmental impacts, solar PV technologies have fewer negative environmental impacts than traditional fossil - fuel - based electricity production.

Lofelt, a Berlin - based startup that is developing «next - generation» haptic technology for use in a range of products — including gaming, AR, VR, automobile, consumer electronics, toys, medical, and entertainment — has raised $ 5.4 million in Series A funding.

About Morgan Solar Based in Toronto, Ontario, Morgan Solar is a technology company founded in 2007 with the goal of making unsubsidized solar energy competitive with traditional sources of generation.

A new partnership between next - generation web browser Brave and the Dow Jones Media Group could introduce new forms of content to online users as well as advance blockchain - based payment technology.

Volvo, which Ford sold to China's Geely Holding in 2010, will also be building out its own autonomous technology using that same base vehicle — the next generation of which will be fully autonomous.

Giving credence to these rumors, Taiwan - based AU Optronics (AUO) reportedly plans to develop a Retina Display for the next - generation iPad Mini, which may require IGZO technology to pull off a feasible Retina Display.

GAME will construct the next generation of decentralized exchange AIDEX jointly with Matrix AI Network based on artificial intelligence and blockchain technology.»

The new FinTech Cluster based at MaRS will connect leaders in the technology and financial services sector with startups developing next generation technology in payments, financial services, peer - to - peer transactions, alternative lending, and crypto - currencies.

In cooperation the multinational corporation based in Switzerland - Hdac Technology AG, HyundaiPay has announced plans to hold a Token Generation Event on the 27th of November, aiming to bring blockchain technology and smart contacts to IoT payment platforms and secure transactions amongst connecteTechnology AG, HyundaiPay has announced plans to hold a Token Generation Event on the 27th of November, aiming to bring blockchain technology and smart contacts to IoT payment platforms and secure transactions amongst connectetechnology and smart contacts to IoT payment platforms and secure transactions amongst connected devices.

Workers from the millennial generation have used technology to create lifestyles based on their own rules.

Based on an IFT short course, Beverage Quality and Safety offers information on the latest beverage industry trends related to products, processing, and packaging technologies - including new generation nutraceutical beverages

She is also the author of Mom 3.0: Marketing With Today's Mothers by Leveraging New Media & Technology, Trillion Dollar Moms: Marketing to a New Generation of Mothers and The Women's Home - Based Business Book of Answers.

The Albany NanoTech Complex is a fully - integrated research, development, prototyping, and educational facility that provides strategic support through outreach, technology acceleration, business incubation, prototyping, and test - based integration support for onsite corporate partners including IBM,, GlobalFoundries, SUNY Poly SEMATECH, Samsung, Applied Materials, Tokyo Electron, and Lam Research, as well as other «next generation» nanotechnology research activities.

This panel combines new generations of FISH technologies, pairing oligonucleotide - based SureFISH technology with a ready - to - use formulation of formamide - free IQ Hybridization Buffer, resulting in high signal - to - noise ratios with less than 4 hours of turnaround time.

On a per - kWh basis, it costs more than some other lithium - ion technologies, but A123's Forcier said it performs better than the one in the first - generation Volt — LG Chem's — and that it can do more with less space.

«Light - based method improves practicality and quality of remote wind measurements: Innovative technology could aid hurricane forecasting, aircraft safety and wind energy generation.»

In one of the memoranda of understanding (MOUs), China's Huaneng Clean Energy Research Institute, a subsidiary of state - owned power company China Huaneng and Washington - based Summit Power Group agreed to share information on clean coal power generation technology.

The mPower reactor is largely based on Generation III reactor technology that NRC is currently reviewing for certification, which should make the small reactor's licensing «conform to existing licensing protocol» and shorten the review time, Mowry said.

I also worry about the next generation of kids around the world growing up with Internet - based technology that emphasizes aggregation, as is the current fad.

«Quantum random number generation as well as quantum cryptography and other quantum - based technologies will benefit from PIC - based technology because it allows one to build commercial and innovative products.

The Vienna University of Technology in collaboration with the company Ivoclar Vivadent have now developed a new generation of photoactive materials based on the element Germanium.

«This technology could have very important applications in ultra-high-speed links for the wireless «backhaul» that connects base stations of next - generation cellular systems,» said Andy Molisch of USC Viterbi.

A University of Colorado Cancer Center study published in the journal Oncogene used next - generation sequencing technologies to perform the most detailed DNA - based analysis to date of 25 commonly used bladder cancer cell lines, allowing researchers to match patient tumors with their closest genetic cell line match, and demonstrated genetic alterations that may make cells more or less sensitive to common therapies.

«This breakthrough holds substantial promise as the base technology for the application of the next - generation solar cells, as well as various IoT devices and displays,» says Professor Jin Young Kim.

Professor Masanobu Izaki and colleagues at Toyohashi University of Technology, in collaboration with researchers at the Research Center for Photovoltaic Technologies, National Institute of Advanced Industrial Science and Technology, have analyzed the structure of a zinc - based buffer layer in a CIGS solar cell at SPring8 (the world's largest third - generation synchrotron radiation facility, located in Hyogo Prefecture, Japan).

Their findings, as depicted in a series of maps illustrating the cost of each generation technology on a county - by - county basis throughout the U.S., are featured in a new white paper titled «New U.S. Power Costs: by County, with Environmental Externalities.»

Due to the high efficiency of establishing organoid models from different tissues and diseases, such as cancer, organoid technology allows the generation of large living biobanks of tumor organoids that are amenable for middle - throughput drug screens and may allow personalized therapy design, as a complement to cell line and xenograft - based drug studies (7,19).

Table 1: Selection, Design & Construction of HSV - based Oncolytic Viruses Table 2: Selection, Design & Construction of Adenovirus - based Oncolytic Viruses Table 3: Selection, Design & Construction of Vaccinia Virus - based Oncolytic Viruses Table 4: Selection, Design & Construction of Vesicular Stomatitis Virus - based Oncolytic Viruses Table 5: Selection, Design & Construction of Newcastle Disease Virus - based Oncolytic Viruses Table 6: Selection, Design & Construction of Various Virus - based Oncolytic Viruses Table 7: Current Company - Sponsored Clinical Trials of T - Vec Table 8: Clinical Trials of ColoAd1 Table 9: Clinical Trials with JX - 594 Table 10: Clinical Trials with GL - ONC1 Table 11: Clinical Trials of CAVATAK (CVA21) Table 12: Clinical Trials with MV - NIS Table 13: Overview of Oncolytic Viruses by Development Phase & Virus Family Table 14: Profile of Approved and Marketed Oncolytic Viruses Table 15: Pivotal Study Design of Oncolytic Viruses in Late Stage Development Based on Previous Clinical Results Table 16: Approved Indications of Immune Checkpoint Inhibitors Table 17: Active Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 18: Planned Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 19: Active or Planned Clinical Studies of Oncolytic Viruses in Combination with Other Anti-Cancer Therapeutics Table 20: Pattern of Transgenes in Oncolytic Viruses in Relation to Development Phase Tables 21a and 21b: Indications and Frquency and Way of Administration of Oncolytic Viruses in Active and / or Positive Completed Clinical Studies Table 22: Small and Medium Pharma & Biotech as Partner for Regional Co-Development of Oncolytic Viruses Table 23: Immuno - Oncology Portfolio of Major Pharma & Biotech with Interest in Oncolytic Viruses Table 24: Interests of Major Pharma & Biotech in Oncolytic Viruses Table 25: First Generation Oncology Virus Companies and their Sources of Technology Table 26: Second Generation Oncology Virus Companies and their Sources of Technology Table 27: Third Generation Oncology Virus Companies and their Sources of Technology Table 28: Fourth Generation Oncology Virus Companies and their Sources of Technology Table 29: Grants, Credits & Donations Table 30: Financing by Venture Capital, Private Equity and Other Private Placements Table 31: Collaboration & Licensing Agreements Table 32: Companies Listed on Stock Exchange & Offerings Table 33: Mergers & Acquisibased Oncolytic Viruses Table 2: Selection, Design & Construction of Adenovirus - based Oncolytic Viruses Table 3: Selection, Design & Construction of Vaccinia Virus - based Oncolytic Viruses Table 4: Selection, Design & Construction of Vesicular Stomatitis Virus - based Oncolytic Viruses Table 5: Selection, Design & Construction of Newcastle Disease Virus - based Oncolytic Viruses Table 6: Selection, Design & Construction of Various Virus - based Oncolytic Viruses Table 7: Current Company - Sponsored Clinical Trials of T - Vec Table 8: Clinical Trials of ColoAd1 Table 9: Clinical Trials with JX - 594 Table 10: Clinical Trials with GL - ONC1 Table 11: Clinical Trials of CAVATAK (CVA21) Table 12: Clinical Trials with MV - NIS Table 13: Overview of Oncolytic Viruses by Development Phase & Virus Family Table 14: Profile of Approved and Marketed Oncolytic Viruses Table 15: Pivotal Study Design of Oncolytic Viruses in Late Stage Development Based on Previous Clinical Results Table 16: Approved Indications of Immune Checkpoint Inhibitors Table 17: Active Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 18: Planned Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 19: Active or Planned Clinical Studies of Oncolytic Viruses in Combination with Other Anti-Cancer Therapeutics Table 20: Pattern of Transgenes in Oncolytic Viruses in Relation to Development Phase Tables 21a and 21b: Indications and Frquency and Way of Administration of Oncolytic Viruses in Active and / or Positive Completed Clinical Studies Table 22: Small and Medium Pharma & Biotech as Partner for Regional Co-Development of Oncolytic Viruses Table 23: Immuno - Oncology Portfolio of Major Pharma & Biotech with Interest in Oncolytic Viruses Table 24: Interests of Major Pharma & Biotech in Oncolytic Viruses Table 25: First Generation Oncology Virus Companies and their Sources of Technology Table 26: Second Generation Oncology Virus Companies and their Sources of Technology Table 27: Third Generation Oncology Virus Companies and their Sources of Technology Table 28: Fourth Generation Oncology Virus Companies and their Sources of Technology Table 29: Grants, Credits & Donations Table 30: Financing by Venture Capital, Private Equity and Other Private Placements Table 31: Collaboration & Licensing Agreements Table 32: Companies Listed on Stock Exchange & Offerings Table 33: Mergers & Acquisibased Oncolytic Viruses Table 3: Selection, Design & Construction of Vaccinia Virus - based Oncolytic Viruses Table 4: Selection, Design & Construction of Vesicular Stomatitis Virus - based Oncolytic Viruses Table 5: Selection, Design & Construction of Newcastle Disease Virus - based Oncolytic Viruses Table 6: Selection, Design & Construction of Various Virus - based Oncolytic Viruses Table 7: Current Company - Sponsored Clinical Trials of T - Vec Table 8: Clinical Trials of ColoAd1 Table 9: Clinical Trials with JX - 594 Table 10: Clinical Trials with GL - ONC1 Table 11: Clinical Trials of CAVATAK (CVA21) Table 12: Clinical Trials with MV - NIS Table 13: Overview of Oncolytic Viruses by Development Phase & Virus Family Table 14: Profile of Approved and Marketed Oncolytic Viruses Table 15: Pivotal Study Design of Oncolytic Viruses in Late Stage Development Based on Previous Clinical Results Table 16: Approved Indications of Immune Checkpoint Inhibitors Table 17: Active Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 18: Planned Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 19: Active or Planned Clinical Studies of Oncolytic Viruses in Combination with Other Anti-Cancer Therapeutics Table 20: Pattern of Transgenes in Oncolytic Viruses in Relation to Development Phase Tables 21a and 21b: Indications and Frquency and Way of Administration of Oncolytic Viruses in Active and / or Positive Completed Clinical Studies Table 22: Small and Medium Pharma & Biotech as Partner for Regional Co-Development of Oncolytic Viruses Table 23: Immuno - Oncology Portfolio of Major Pharma & Biotech with Interest in Oncolytic Viruses Table 24: Interests of Major Pharma & Biotech in Oncolytic Viruses Table 25: First Generation Oncology Virus Companies and their Sources of Technology Table 26: Second Generation Oncology Virus Companies and their Sources of Technology Table 27: Third Generation Oncology Virus Companies and their Sources of Technology Table 28: Fourth Generation Oncology Virus Companies and their Sources of Technology Table 29: Grants, Credits & Donations Table 30: Financing by Venture Capital, Private Equity and Other Private Placements Table 31: Collaboration & Licensing Agreements Table 32: Companies Listed on Stock Exchange & Offerings Table 33: Mergers & Acquisibased Oncolytic Viruses Table 4: Selection, Design & Construction of Vesicular Stomatitis Virus - based Oncolytic Viruses Table 5: Selection, Design & Construction of Newcastle Disease Virus - based Oncolytic Viruses Table 6: Selection, Design & Construction of Various Virus - based Oncolytic Viruses Table 7: Current Company - Sponsored Clinical Trials of T - Vec Table 8: Clinical Trials of ColoAd1 Table 9: Clinical Trials with JX - 594 Table 10: Clinical Trials with GL - ONC1 Table 11: Clinical Trials of CAVATAK (CVA21) Table 12: Clinical Trials with MV - NIS Table 13: Overview of Oncolytic Viruses by Development Phase & Virus Family Table 14: Profile of Approved and Marketed Oncolytic Viruses Table 15: Pivotal Study Design of Oncolytic Viruses in Late Stage Development Based on Previous Clinical Results Table 16: Approved Indications of Immune Checkpoint Inhibitors Table 17: Active Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 18: Planned Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 19: Active or Planned Clinical Studies of Oncolytic Viruses in Combination with Other Anti-Cancer Therapeutics Table 20: Pattern of Transgenes in Oncolytic Viruses in Relation to Development Phase Tables 21a and 21b: Indications and Frquency and Way of Administration of Oncolytic Viruses in Active and / or Positive Completed Clinical Studies Table 22: Small and Medium Pharma & Biotech as Partner for Regional Co-Development of Oncolytic Viruses Table 23: Immuno - Oncology Portfolio of Major Pharma & Biotech with Interest in Oncolytic Viruses Table 24: Interests of Major Pharma & Biotech in Oncolytic Viruses Table 25: First Generation Oncology Virus Companies and their Sources of Technology Table 26: Second Generation Oncology Virus Companies and their Sources of Technology Table 27: Third Generation Oncology Virus Companies and their Sources of Technology Table 28: Fourth Generation Oncology Virus Companies and their Sources of Technology Table 29: Grants, Credits & Donations Table 30: Financing by Venture Capital, Private Equity and Other Private Placements Table 31: Collaboration & Licensing Agreements Table 32: Companies Listed on Stock Exchange & Offerings Table 33: Mergers & Acquisibased Oncolytic Viruses Table 5: Selection, Design & Construction of Newcastle Disease Virus - based Oncolytic Viruses Table 6: Selection, Design & Construction of Various Virus - based Oncolytic Viruses Table 7: Current Company - Sponsored Clinical Trials of T - Vec Table 8: Clinical Trials of ColoAd1 Table 9: Clinical Trials with JX - 594 Table 10: Clinical Trials with GL - ONC1 Table 11: Clinical Trials of CAVATAK (CVA21) Table 12: Clinical Trials with MV - NIS Table 13: Overview of Oncolytic Viruses by Development Phase & Virus Family Table 14: Profile of Approved and Marketed Oncolytic Viruses Table 15: Pivotal Study Design of Oncolytic Viruses in Late Stage Development Based on Previous Clinical Results Table 16: Approved Indications of Immune Checkpoint Inhibitors Table 17: Active Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 18: Planned Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 19: Active or Planned Clinical Studies of Oncolytic Viruses in Combination with Other Anti-Cancer Therapeutics Table 20: Pattern of Transgenes in Oncolytic Viruses in Relation to Development Phase Tables 21a and 21b: Indications and Frquency and Way of Administration of Oncolytic Viruses in Active and / or Positive Completed Clinical Studies Table 22: Small and Medium Pharma & Biotech as Partner for Regional Co-Development of Oncolytic Viruses Table 23: Immuno - Oncology Portfolio of Major Pharma & Biotech with Interest in Oncolytic Viruses Table 24: Interests of Major Pharma & Biotech in Oncolytic Viruses Table 25: First Generation Oncology Virus Companies and their Sources of Technology Table 26: Second Generation Oncology Virus Companies and their Sources of Technology Table 27: Third Generation Oncology Virus Companies and their Sources of Technology Table 28: Fourth Generation Oncology Virus Companies and their Sources of Technology Table 29: Grants, Credits & Donations Table 30: Financing by Venture Capital, Private Equity and Other Private Placements Table 31: Collaboration & Licensing Agreements Table 32: Companies Listed on Stock Exchange & Offerings Table 33: Mergers & Acquisibased Oncolytic Viruses Table 6: Selection, Design & Construction of Various Virus - based Oncolytic Viruses Table 7: Current Company - Sponsored Clinical Trials of T - Vec Table 8: Clinical Trials of ColoAd1 Table 9: Clinical Trials with JX - 594 Table 10: Clinical Trials with GL - ONC1 Table 11: Clinical Trials of CAVATAK (CVA21) Table 12: Clinical Trials with MV - NIS Table 13: Overview of Oncolytic Viruses by Development Phase & Virus Family Table 14: Profile of Approved and Marketed Oncolytic Viruses Table 15: Pivotal Study Design of Oncolytic Viruses in Late Stage Development Based on Previous Clinical Results Table 16: Approved Indications of Immune Checkpoint Inhibitors Table 17: Active Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 18: Planned Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 19: Active or Planned Clinical Studies of Oncolytic Viruses in Combination with Other Anti-Cancer Therapeutics Table 20: Pattern of Transgenes in Oncolytic Viruses in Relation to Development Phase Tables 21a and 21b: Indications and Frquency and Way of Administration of Oncolytic Viruses in Active and / or Positive Completed Clinical Studies Table 22: Small and Medium Pharma & Biotech as Partner for Regional Co-Development of Oncolytic Viruses Table 23: Immuno - Oncology Portfolio of Major Pharma & Biotech with Interest in Oncolytic Viruses Table 24: Interests of Major Pharma & Biotech in Oncolytic Viruses Table 25: First Generation Oncology Virus Companies and their Sources of Technology Table 26: Second Generation Oncology Virus Companies and their Sources of Technology Table 27: Third Generation Oncology Virus Companies and their Sources of Technology Table 28: Fourth Generation Oncology Virus Companies and their Sources of Technology Table 29: Grants, Credits & Donations Table 30: Financing by Venture Capital, Private Equity and Other Private Placements Table 31: Collaboration & Licensing Agreements Table 32: Companies Listed on Stock Exchange & Offerings Table 33: Mergers & Acquisibased Oncolytic Viruses Table 7: Current Company - Sponsored Clinical Trials of T - Vec Table 8: Clinical Trials of ColoAd1 Table 9: Clinical Trials with JX - 594 Table 10: Clinical Trials with GL - ONC1 Table 11: Clinical Trials of CAVATAK (CVA21) Table 12: Clinical Trials with MV - NIS Table 13: Overview of Oncolytic Viruses by Development Phase & Virus Family Table 14: Profile of Approved and Marketed Oncolytic Viruses Table 15: Pivotal Study Design of Oncolytic Viruses in Late Stage Development Based on Previous Clinical Results Table 16: Approved Indications of Immune Checkpoint Inhibitors Table 17: Active Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 18: Planned Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 19: Active or Planned Clinical Studies of Oncolytic Viruses in Combination with Other Anti-Cancer Therapeutics Table 20: Pattern of Transgenes in Oncolytic Viruses in Relation to Development Phase Tables 21a and 21b: Indications and Frquency and Way of Administration of Oncolytic Viruses in Active and / or Positive Completed Clinical Studies Table 22: Small and Medium Pharma & Biotech as Partner for Regional Co-Development of Oncolytic Viruses Table 23: Immuno - Oncology Portfolio of Major Pharma & Biotech with Interest in Oncolytic Viruses Table 24: Interests of Major Pharma & Biotech in Oncolytic Viruses Table 25: First Generation Oncology Virus Companies and their Sources of Technology Table 26: Second Generation Oncology Virus Companies and their Sources of Technology Table 27: Third Generation Oncology Virus Companies and their Sources of Technology Table 28: Fourth Generation Oncology Virus Companies and their Sources of Technology Table 29: Grants, Credits & Donations Table 30: Financing by Venture Capital, Private Equity and Other Private Placements Table 31: Collaboration & Licensing Agreements Table 32: Companies Listed on Stock Exchange & Offerings Table 33: Mergers & AcquisiBased on Previous Clinical Results Table 16: Approved Indications of Immune Checkpoint Inhibitors Table 17: Active Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 18: Planned Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI) Table 19: Active or Planned Clinical Studies of Oncolytic Viruses in Combination with Other Anti-Cancer Therapeutics Table 20: Pattern of Transgenes in Oncolytic Viruses in Relation to Development Phase Tables 21a and 21b: Indications and Frquency and Way of Administration of Oncolytic Viruses in Active and / or Positive Completed Clinical Studies Table 22: Small and Medium Pharma & Biotech as Partner for Regional Co-Development of Oncolytic Viruses Table 23: Immuno - Oncology Portfolio of Major Pharma & Biotech with Interest in Oncolytic Viruses Table 24: Interests of Major Pharma & Biotech in Oncolytic Viruses Table 25: First Generation Oncology Virus Companies and their Sources of Technology Table 26: Second Generation Oncology Virus Companies and their Sources of Technology Table 27: Third Generation Oncology Virus Companies and their Sources of Technology Table 28: Fourth Generation Oncology Virus Companies and their Sources of Technology Table 29: Grants, Credits & Donations Table 30: Financing by Venture Capital, Private Equity and Other Private Placements Table 31: Collaboration & Licensing Agreements Table 32: Companies Listed on Stock Exchange & Offerings Table 33: Mergers & Acquisitions

Synthetic Genomics (SGI) and the J. Craig Venter Institute (JCVI) have formed a new company, Synthetic Genomics Vaccines (SGVI), to develop next - generation vaccines based on synthetic genome technology.

Engineering the space - time metric - Develop next - generation aerospace propulsion technologies, using a concept referred to as metric engineering, which uses advanced math modelling techniques, providing a technology base to the Aerospace Division for future products.

Developed in collaboration with the Laboratory Medicine, Information Technology and Health Science Research departments of Mayo Clinic Geneticist Assistant NGS Interpretative Workbench, is a web - based tool for the control, visualization, interpretation and historical knowledge base of next generation sequencing data targeted at specific genes for the purpose of identifying potentially pathogenic variants associated with specific conditions such as hereditary colon cancer.

Concretely, based on basic research on nanoscale materials, such as atomic and molecular transport and chemical reaction processes, polarization and excitation of charge and spin and superconducting phenomena, we are conducting research on atomic switches, artificial synapses, molecular devices, new quantum bits, neural network - type network circuits, next - generation devices, high sensitivity integrated molecular sensors and other new applied technologies.

Next generation sequencing (NGS) technologies, primarily based on massively parallel sequencing (MPS), have touched and radically changed almost all aspects of research worldwide.

We developed a new approach to sequence generation for targeted base updates and used data from new genome mapping technologies and single haplotype resources to identify and resolve larger assembly issues.

We report a third - generation sequencing assay on nanopore technology (MinION) for detecting BCR - ABL1 KD mutations and compare the results to a Sanger sequencing (SS)- based test in 24 Philadelphia - positive (Ph +) leukemia cases.

Next - generation sequencing involves the application of glass micro-chip based methods and small - volume liquid handling (microfluidics) to sequence DNA more quickly and more cheaply than ever before, indeed 1000s times less costly than the technology used to sequence the first human genome just a few years ago.

The two companies hope to advance an aSMR design for global power generation with initial deployment in Canada, including the pursuit of a preliminary regulatory review by the Canadian Nuclear Safety Commission, based on earlier technology licensing success in the United States.

The Genomics Innovation Hub, led by the University of Melbourne and the Australian Genomics Research Facility (AGRF), will provide critical next - generation technology and analytics capacity that will ultimately pave the way for personalised treatments based on patients» genetic profiles.

Stafford, Texas About Blog SalesStaff provides demand generation services for business - to - business technology companies through the deployment and management of quota - based marketing programs.

The Company has letters of intent to acquire: Web Diversity Limited (London - based paid search management, organic search), Crystal Semantics and Crystal Reference (internet content and search technology, European educational content), iLead Media (online lead generation), Litmus Media (secure ad feed distribution).

meetMoi, the leading mobile dating company in the United States and one of the first to utilize location - based technology, has released virtual gifting as a new opportunity for user - to - user interaction as well as revenue generation.

Generations Can Connect, a different kind of technology - based service - learning project, was piloted at the Banded Peak School in Bragg Creek, Alberta, Canada.

In 10 or 20 years, when that new generation starts school, it may have changed again, but currently, cloud - based technologies at the classroom level are quickly becoming some of the best and most versatile tools on the market.

Mobile learning is the next step for this industry, whereas game - based learning apps can be a great use of technology for future generations.